ICD 10 Code for Prostate Cancer: Complete Coding Guide

What Is the ICD 10 Code for Prostate Cancer?

C61 is a code that can be billed for confirmed prostate cancer. This includes prostate adenocarcinoma. The code is used under the FY 2027 ICD-10-CM guidelines. The guidelines are in effect from October 1 2026 to September 30 2027.

The diagnosis needs to be backed up by notes, from the provider. High levels of PSA having a prostate that is not cancerous or just having a regular check-up by itself is not enough to say someone has prostate cancer.

Follow the coding rules when dealing with hormone sensitivity and if PSA levels go up after treatment.

Prostate Cancer ICD-10-CM Codes and Related Diagnoses

The following table distinguishes active prostate cancer from related findings, previous malignancy, and metastatic disease.

These codes serve different purposes. Codes should not appear together automatically just because a patient has a history of prostate cancer.

The physicians documented findings, the disease status, the treatment and the reason, for the encounter determine which codes apply.

When Should Physicians Use C61 or Z85.46?

Distinguishing active malignancy from personal history is one of the most important decisions in prostate cancer coding.

Active prostate cancer: C61

Use C61 when the documentation supports a current primary prostate malignancy.

For example, a patient undergoing radiation therapy for confirmed prostate cancer still has an active diagnosis for coding purposes.

Likewise, cancer managed through active surveillance remains a current malignancy. Active surveillance does not mean the disease has resolved.

Personal history of prostate cancer: Z85.46

Use Z85.46 when the previous primary cancer has been removed or destroyed there is no sign of cancer at that location. No more treatment is being done at that location.

Consider the patient who had a prostatectomy years ago. The patient now comes for cancer checks. If the records show that the treatment is complete and the patient does not have cancer then the code Z85.46 could be the code.

Important: Just because the prostate is gone does not mean that prostate cancer should be coded as a history. If there is still cancer. If cancer comes back or if cancer spreads or if the patient is still getting treatment then the current medical records need to be checked.

The official ICD-10-CM guidelines say that current cancer is different, from a history. The difference is based on the status of the disease and the treatment not how ago the surgery was done.

ICD 10 Codes for Metastatic Prostate Cancer

Prostate cancer can spread beyond the tumor especially to bones and lymph nodes. When prostate cancer spreads the diagnosis record should identify each confirmed site.

For instance, a patient with documented prostate cancer and bone metastases may require:

• C61: Primary malignant neoplasm of prostate.

• C79.51: Secondary malignant neoplasm of bone.

The sequencing depends on the reason for treatment.

When care is centered on the prostate cancer C61 usually comes first. If treatment is for a secondary cancer site then the metastatic diagnosis might be listed as the primary diagnosis.

Providers must not code metastases based on unclear imaging results during outpatient visits if the diagnosis is still not confirmed.

Clear and detailed documentation also supports the need, for advanced imaging, radiation therapy and oncology procedures.

How to Code Rising PSA After Prostate Cancer Treatment

A rising PSA level after prostate cancer treatment creates a different coding situation from a newly diagnosed primary malignancy.

R97.21 identifies rising PSA following treatment for malignant neoplasm of the prostate.

For example, a patient who previously underwent prostatectomy returns with progressively increasing PSA values. The physician evaluates the laboratory results but has not yet established whether active recurrent malignancy is present.

In this situation, R97.21 may describe the documented finding. The coding team should not independently diagnose recurrent cancer from the laboratory values.

If the physician establishes recurrent prostate cancer, code the confirmed malignancy as appropriate and follow the additional-code instructions applicable to C61.

Accurate documentation should explain the PSA trend, prior treatment, current assessment, and reason for further testing.

CPT Codes Used in Prostate Cancer Diagnosis and Treatment

ICD-10-CM codes identify the patient’s diagnosis, while Current Procedural Terminology (CPT) codes describe the services performed.

Urology practices must connect these codes correctly to support medical necessity and accurate reimbursement.

Common Prostate Cancer CPT and HCPCS Codes

2026–2027 coding update: CPT 55700 was deleted effective January 2026. The replacement biopsy CPT codes show the approach and the imaging guidance used. Additional prostate biopsy CPT code revisions are planned for January 2027 so you should verify the CPT code set that is in force, on the day the service is performed.

The procedure documentation must support the reported service. For example, a standard transrectal ultrasound-guided prostate biopsy and an MRI-fusion-guided biopsy do not use identical procedural coding.

Practices must also review bundled services, the applicable National Correct Coding Initiative (NCCI) edits and payer policies before adding imaging or other separately reported procedures.

Prostate Cancer Screening vs. Diagnostic PSA Billing

Screening and diagnostic PSA testing have different billing requirements.

Screening PSA testing helps identify possible prostate cancer in an individual without a confirmed diagnosis or symptoms being evaluated.

For eligible Medicare beneficiaries, G0103 identifies the screening PSA test, with Z12.5 commonly supporting the screening encounter.

Diagnostic PSA testing, on the other hand, evaluates a clinical concern or monitors an established condition. CPT 84153 represents total PSA testing for diagnostic or monitoring purposes.

Consider two patients:

A 55-year-old person who has Medicare goes to an appointment for prostate cancer screening. The medical office can use the code G0103 along with Z12.5 if the rules for coverage are met.

Another person has a PSA test because a doctor is keeping an eye on prostate cancer that was treated before. The medical office should pick the code for a diagnostic service and the correct diagnosis based on what is written in the medical records. They should not treat the test as a checkup.

Medicare usually pays for prostate cancer screening tests at times each year for men who are 50 or older. Rules, from health insurance companies can be different.

Common Modifiers Used in Prostate Cancer Billing

Modifiers communicate details about how healthcare professionals perform or bill services. They do not establish medical necessity or independently guarantee payment.

For example a urologist may give an evaluation. Do a procedure during the same visit. Modifier 25 may only fit when the evaluation is a separate task that goes beyond the usual services linked to the procedure.

Similarly, modifier 59 should not be added simply because two procedure codes trigger a bundling edit. The documentation and applicable coding rules must establish that separate reporting is permitted.

Common Prostate Cancer Billing Denials and CARC Codes

Prostate cancer claims can be denied because the diagnosis isn’t supported, authorizations are missing there are coding mistakes coverage rules aren’t followed or there is not enough documentation.

The following Claim Adjustment Reason Codes (CARCs) might show up on claims related to prostate cancer services.

The actual adjustment group code and reason depend on payer adjudication. The examples above should not be interpreted as guaranteed outcomes for particular prostate cancer services.

The official CARC list explains standardized payment adjustment reasons.

Relevant Remittance Advice Remark Codes

Remittance Advice Remark Codes (RARCs) provide additional information about claim processing and adjustments.

These are general remittance codes that may be relevant to prostate cancer claims; they are not exclusive to oncology or urology.

A billing team should review the full electronic remittance advice, including the adjustment group, CARC, RARC, and applicable payer policy, before correcting or appealing a claim.

Documentation Requirements for Accurate Prostate Cancer Coding

Physicians do not need to change their clinical judgment to meet billing requirements. They do, however, need to document the findings that support the diagnosis and service.

A clear prostate cancer record should establish:

• Disease status: Whether malignancy is active, previously treated, recurrent, or metastatic.

• Diagnostic confirmation: Relevant pathology, clinical assessment, or other documentation supporting the diagnosis.

• Metastatic involvement: Confirmed secondary sites, when applicable.

• Treatment status: Whether the patient receives surgery, radiation, systemic therapy, active surveillance, or post-treatment follow-up.

• PSA findings: Relevant results, trends, and clinical interpretation.

• Reason for the encounter: The condition or service primarily responsible for the visit.

For example, a note stating only “prostate cancer follow-up” may create uncertainty about current disease status.

A more useful assessment could document that the patient completed treatment, has no current evidence of disease, and attends a scheduled surveillance visit.

This distinction helps coders identify whether the record supports C61, Z85.46, Z08, or another diagnosis code.

Clear documentation can reduce unnecessary provider queries, claim corrections, and repeated payer requests for records.

How Diagnosis Sequencing Affects Prostate Cancer Claims

Diagnosis sequencing communicates the clinical reason for the service.

Three common situations illustrate how sequencing changes.

An important exception applies when an encounter is solely for the administration of qualifying antineoplastic chemotherapy, immunotherapy, or radiation therapy. The appropriate Z51 encounter code generally takes precedence, followed by the malignancy diagnosis.

Providers and coders should follow the current official neoplasm sequencing guidelines rather than routinely placing C61 first on every claim.

How to Reduce Prostate Cancer Billing Errors

Even when the diagnosis is correct, avoidable administrative errors can delay claims.

Urology and oncology practices can strengthen their billing processes by focusing on four areas.

Verify the current diagnosis

Confirm whether the record describes active cancer, historical disease, metastatic cancer, or an abnormal finding.

Do not replace the physician’s diagnosis with an interpretation based solely on pathology excerpts or PSA results.

Review the procedure details

Before submitting biopsy or surgery claims, verify that the operative report supports the chosen CPT code.

For prostate biopsy services, the procedure approach, imaging guidance, and targeted sampling can change code selection.

Confirm coverage before treatment

For services requiring prior authorization, verify payer requirements before the scheduled treatment whenever possible.

The team should also review frequency restrictions and applicable coverage policies for screening, imaging, medication administration and radiation services.

Investigate denials individually

Do not assume every prostate cancer denial stems from an incorrect diagnosis code.

A claim may involve an authorization issue, benefit exclusion, missing modifier, or procedural bundling restriction.

Maryland Medical Billing helps healthcare practices address these revenue cycle challenges by supporting accurate claim preparation, coding reviews, denial management and billing follow-up.

Frequently Asked Questions

What is the ICD 10 code for prostate cancer?

The ICD-10-CM code for confirmed primary prostate cancer is C61 – Malignant neoplasm of prostate. It applies when documentation establishes a current primary prostate malignancy.

What is the ICD 10 code for a history of prostate cancer?

Z85.46 represents a personal history of malignant neoplasm of the prostate. It is appropriate when the previously treated primary malignancy meets the ICD-10-CM history coding criteria.

What is the ICD 10 code for metastatic prostate cancer?

The primary prostate cancer code is C61 when the primary malignancy remains current. Additional codes identify confirmed metastatic sites, such as C79.51 for bone metastasis or C77.5 for intrapelvic lymph node involvement.

Is elevated PSA the same as prostate cancer?

No. An elevated PSA result does not independently confirm prostate cancer. R97.20 identifies elevated PSA, while R97.21 identifies rising PSA after treatment for prostate malignancy.

What code is used for prostate cancer screening?

Z12.5 identifies an encounter for screening for malignant neoplasm of the prostate. For eligible Medicare screening PSA services, G0103 is the applicable HCPCS code.

Can C61 and Z85.46 be billed together?

They generally should not both describe the same prostate primary as simultaneously active and historical. Coding may become more complex when a patient has a former primary site and current metastatic disease. The documented disease status and official guidelines determine the correct combination.

Does C61 require an additional ICD-10-CM code?

Sometimes. The C61 classification includes instructions for applicable hormone-sensitivity status and rising PSA following treatment. Confirmed metastatic sites and separately reportable conditions may also require additional codes.

Conclusion

Accurate prostate cancer coding starts with determining whether the patient has active malignancy, previously treated disease, metastatic involvement, or a screening-related encounter.

Although C61 is the primary ICD 10 code for prostate cancer, successful claim preparation also depends on selecting appropriate related diagnosis codes, matching CPT procedures to documented services and following payer-specific coverage requirements.

Practices that maintain clear clinical records and review coding changes can reduce preventable denials and support more efficient reimbursement.

Get Support With Prostate Cancer Medical Billing

Managing prostate cancer claims requires consistent attention to diagnosis coding, procedure selection, authorizations and payer requirements.

Maryland Medical Billing provides medical billing and revenue cycle management services to help urology and oncology practices improve claim accuracy, address denied claims and reduce administrative workload.

Contact our billing team today to discuss your practice’s medical billing needs.